CME/CE

This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.

This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.

This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.

Our experts review updated KDIGO practice guideline recommendations for proteinuria reduction in IgA nephropathy (IgAN) and their implications for clinical care. Drs. Chee Kay Cheung and Claudia Seikrit examine the shift toward lower proteinuria targets (<0.3 g/day) and the rationale for earlier, more intensive intervention, emphasizing proteinuria as a key predictor of long-term kidney outcomes. The conversation highlights evidence supporting aggressive and sustained reduction strategies across a broader patient population, as well as the clinical relevance of additional markers such as microscopic hematuria. The faculty also discuss IgAN disease mechanisms and therapeutic approaches, including the role of sparsentan and emerging combination strategies, with reference to data from studies such as SPARTAN and SPARTACUS and biomarker analyses involving urinary soluble CD163. Practical considerations for timely treatment initiation and optimizing long-term kidney preservation are also addressed.

This program addresses critical practice gaps in the evaluation and management of non-arteritic anterior ischemic optic neuropathy (NAION). Faculty will review acute ischemic pathophysiology, diagnostic variability, and structured approaches to improve diagnostic accuracy and readiness for clinical trials. Through case-based discussions, participants will learn how to identify key mimickers (eg, optic neuritis, AION) through targeted testing, apply evidence-based evaluation pathways, improve documentation practices, and recognize referral scenarios.

The program will also highlight the impact of systemic risk factors, including GLP-1 receptor agonists, and provide the latest data on investigational agents like cenegermin and privosegtor. Designed for neuro-ophthalmologists, ophthalmologists, and neurologists, this activity supports enhanced diagnostic precision, informed patient counseling, and preparation for emerging NAION therapies.

There have been exciting advances in the treatment of psoriasis. Join Drs. April Armstrong and Melinda Gooderham for this expert discussion to learn about the most recent data on TKY2 inhibitors, presented at the American Academy of Dermatology Annual Meeting in Denver, Colorado.

Recent updates to the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD) emphasized the expanded role of IV iron replacement therapy in patients with non–dialysis-dependent CKD. The updated guidance emphasizes proactive iron assessment, earlier identification of iron deficiency phenotypes, and individualized selection of iron replacement strategies to improve long-term patient outcomes. Other updates include reclassification of systemic iron deficiency and iron-restricted anemia, plus screening recommendations for iron deficiency and iron-deficient anemia.

Despite major advances in prophylaxis and supportive care, hemophilia continues to disrupt daily life, limit function, and compromise long-term well-being for many patients. Joint bleeding, subclinical bleeding, and progressive arthropathy remain important concerns, even in the modern treatment era, with ongoing impacts on pain, mobility, and health-related quality of life. Clinicians must keep pace with shifting treatment strategies, including updated factor VIII (FVIII) target levels from recent guidelines to mediate bleeding protection and the growing role of rebalancing agents. To deliver optimal care, healthcare professionals need a clearer understanding of how to preserve joint health across the lifespan, apply evolving treatment targets judiciously, and select and integrate therapies in ways that reflect the latest clinical evidence, patient priorities, and treatment burden. This activity addresses these needs through expert-led discussions focused on long-term joint outcomes, FVIII-targeted treatment strategies, and the practical clinical integration of rebalancing agents.

Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.